Ken Takeshita, Daiichi Sankyo R&D chief
Enhertu nabs priority review for NSCLC as AstraZeneca and Daiichi Sankyo continue charting a blockbuster course
As AstraZeneca and Daiichi Sankyo continue to outline their blockbuster plans for the antibody-drug conjugate Enhertu, the FDA is giving them an assist.
Regulators awarded …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.